Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA CEO Says ‘CBO Numbers Tell the Story’

Washington, DC, February 15, 2013 — In a blog posting on The Hill’s Congress Blog, Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani writes : 

“In this era of deficit debates and fiscal cliffs, Washington, DC is focused on large numbers and complex math.  In the State of the Union address, the President discussed many numbers and there is no doubt robust debate filled with even more calculations will follow.  And these numbers often lead to very differing views. 

“There is one thing, however, most policymakers can agree on.  The arbiter of Washington’s numbers is the Congressional Budget Office (CBO) .… When CBO speaks, Washington listens. 

“Of note, the CBO recently updated its methodology for calculating the cost of Medicare policies to reflect the effect of prescription medicines on total medical costs.  For the first time, the CBO will begin to account for the savings from use of medicines that reduce the need for other costly medical services, such as hospitalizations.”

Mr. Castellani continues to write on The Hill’s blog:

“As policymakers consider the future of Medicare, it will be critical to recognize the value of medicines and their offsetting effect on other medical spending.  Otherwise, short-term policies designed to produce quick savings could result in unintended consequences.

“Those consequences are likely to be increased costs borne by taxpayers today and by future generations.  But perhaps even more importantly, poorer health outcomes would jeopardize the health and quality of life for many Americans.  With this in mind, policymakers should take a fresh look at what the numbers reveal.”

To read Mr. Castellani’s entire blog posting, click here.